Literature DB >> 26897738

Reply to the letter by Takeshi Yamada et al. concerning "Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?".

Jun Zhou1, Zhi Peng1, Lin Shen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26897738     DOI： 10.1007/s00535-016-1185-1

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  3 in total

1.  Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.

Authors:  Jun Zhou; Zhi Peng; Yi Liu; Jifang Gong; Xiaotian Zhang; Ming Lu; Jing Gao; Yili Li; Yanyan Li; Lin Shen
Journal:  J Gastroenterol       Date:  2015-02-22       Impact factor: 7.527

Review 2.  Challenges in the clinical utility of the serum test for HER2 ECD.

Authors:  Lian Lam; Nicholas McAndrew; Marla Yee; Ting Fu; Julia C Tchou; Hongtao Zhang
Journal:  Biochim Biophys Acta       Date:  2012-04-03

3.  Evaluation of serum HER2-ECD levels in patients with gastric cancer.

Authors:  Katsunobu Oyama; Sachio Fushida; Tomoya Tsukada; Jun Kinoshita; Toshifumi Watanabe; Masatoshi Shoji; Shinichi Nakanuma; Koichi Okamoto; Seisho Sakai; Isamu Makino; Keishi Nakamura; Hironori Hayashi; Masafumi Inokuchi; Hisatoshi Nakagawara; Tomoharu Miyashita; Hidehiro Tajima; Hiroyuki Takamura; Itasu Ninomiya; Hirohisa Kitagawa; Takashi Fujimura; Ryousuke Tajiri; Akishi Ooi; Tetsuo Ohta
Journal:  J Gastroenterol       Date:  2014-02-21       Impact factor: 7.527
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.